GPC Biotech AG (DE) - GPC Biotech to Present at UBS Global Life Sc ...

Montag, 25.09.2006 18:24 von Hugin

http://www.gpc-biotech.com/" target="_new">
http://www.huginonline.de/GPC/logo.gif" ="0" alt="GPC Biotech AG">



Published: 18:23 25.09.2006 GMT+2 /HUGIN /Source: GPC Biotech AG 
/GER: GPC /ISIN: DE0005851505

GPC Biotech to Present at UBS Global Life Sciences Conference in New York City


Martinsried/Munich (Germany), Waltham, Mass. and Princeton, N.J., September 25, 2006 - GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX 30; NASDAQ: GPCB) today announced that the Company will present at the UBS Global Life Sciences Conference in New York, NY.
 
The presentation is scheduled for tomorrow, Tuesday, September 26, 2006, 12:00 PM EDT/18:00 CEST at The Grand Hyatt New York. The presentation will be webcast live and will be accessible through the GPC Biotech Web site at www.gpc-biotech.com. A replay will be available via the Web site after the live event. 
 
GPC Biotech AG is a biopharmaceutical company discovering and developing new anticancer drugs. The Company's lead product candidate - satraplatin - has achieved target enrollment in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and GPC Biotech has begun the rolling NDA submission process for this compound.  GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional information, please visit the Company's Web site at http://www.gpc-biotech.com/" class="hugin">www.gpc-biotech.com. 
 
For further information, please contact:
 
GPC Biotech AG 
Martin Braendle 
Director, Investor Relations & Corporate Communications 
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com 
 
In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 781-890-9007 X267
usinvestors@gpc-biotech.com




This content was distributed through

">http://www.hugincorporate.com">
http://www.huginonline.com/img/hugin/online/hug_m.gif" alt="Hugin Group" hspace="18" width="80px" heigh="34px"> 

- connecting communication professionals with their target audience. Visit">http://www.hugincorporate.com">Visit us here.
Unsubscribe">http://www.huginonline.com/plsql/try/unsubscribe.unsub">Unsubscribe